CA2979713A1 - Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack - Google Patents

Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack Download PDF

Info

Publication number
CA2979713A1
CA2979713A1 CA2979713A CA2979713A CA2979713A1 CA 2979713 A1 CA2979713 A1 CA 2979713A1 CA 2979713 A CA2979713 A CA 2979713A CA 2979713 A CA2979713 A CA 2979713A CA 2979713 A1 CA2979713 A1 CA 2979713A1
Authority
CA
Canada
Prior art keywords
antibody
hae
administered
subject
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2979713A
Other languages
English (en)
French (fr)
Inventor
Yung CHYUNG
Burt Adelman
Daniel J. Sexton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57005262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2979713(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of CA2979713A1 publication Critical patent/CA2979713A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2979713A 2015-03-30 2016-03-30 Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack Pending CA2979713A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562140289P 2015-03-30 2015-03-30
US201562140277P 2015-03-30 2015-03-30
US62/140,289 2015-03-30
US62/140,277 2015-03-30
US201562214293P 2015-09-04 2015-09-04
US62/214,293 2015-09-04
PCT/US2016/024921 WO2016160926A1 (en) 2015-03-30 2016-03-30 Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack

Publications (1)

Publication Number Publication Date
CA2979713A1 true CA2979713A1 (en) 2016-10-06

Family

ID=57005262

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2979713A Pending CA2979713A1 (en) 2015-03-30 2016-03-30 Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack

Country Status (14)

Country Link
US (2) US20180298110A1 (cg-RX-API-DMAC7.html)
EP (2) EP3286226A4 (cg-RX-API-DMAC7.html)
JP (3) JP7008920B2 (cg-RX-API-DMAC7.html)
KR (3) KR102607829B1 (cg-RX-API-DMAC7.html)
CN (1) CN107614532A (cg-RX-API-DMAC7.html)
AU (3) AU2016243160B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017020864A2 (cg-RX-API-DMAC7.html)
CA (1) CA2979713A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017009404A2 (cg-RX-API-DMAC7.html)
EA (1) EA201792161A1 (cg-RX-API-DMAC7.html)
HK (1) HK1250995A1 (cg-RX-API-DMAC7.html)
IL (2) IL305207A (cg-RX-API-DMAC7.html)
MX (2) MX2017012423A (cg-RX-API-DMAC7.html)
WO (1) WO2016160926A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3459564T1 (sl) 2010-01-06 2022-06-30 Takeda Pharmaceutical Company Limited Proteini, ki vežejo plazemski kalikrein
JP2014506257A (ja) 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
CN111704672B (zh) 2013-03-15 2024-06-04 武田药品工业株式会社 抗血浆激肽释放酶抗体
EA038532B1 (ru) 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
IL295414B1 (en) 2014-03-27 2025-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
US11286307B2 (en) * 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
BR112019005167A2 (pt) * 2016-09-16 2019-07-02 Dyax Corp. método e kit para analisar uma amostra
JP7210540B2 (ja) * 2017-08-04 2023-01-23 武田薬品工業株式会社 血漿カリクレインの阻害剤およびその使用
WO2019166572A1 (en) * 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
CA3092538A1 (en) * 2018-02-28 2019-09-06 Lifesci Pharmaceuticals, Inc. Treatment of hereditary angioedema
MX2021002349A (es) * 2018-08-30 2021-05-31 Takeda Pharmaceuticals Co Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
CN114166924B (zh) * 2021-12-03 2024-11-22 中国医学科学院北京协和医院 尿液蛋白标志物在诊断遗传性血管水肿中的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
ES2227545T3 (es) 1994-01-11 2005-04-01 Dyax Corporation Proteinas y sus analogos del "dominio de kunitz" inhibidores de calicreina.
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DE60333758D1 (de) 2002-06-07 2010-09-23 Dyax Corp Prevention und Verringerung von Ischemia
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
SI3459564T1 (sl) * 2010-01-06 2022-06-30 Takeda Pharmaceutical Company Limited Proteini, ki vežejo plazemski kalikrein
JP2014506257A (ja) * 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
WO2012151247A2 (en) * 2011-05-02 2012-11-08 Millennium Pharmaceuticals, Inc. FORMULATION FOR ANTI-α4β7 ANTIBODY
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
EP3456744B1 (en) * 2013-01-20 2023-03-29 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
CN111704672B (zh) * 2013-03-15 2024-06-04 武田药品工业株式会社 抗血浆激肽释放酶抗体
KR20140119396A (ko) * 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
AU2014340450B2 (en) * 2013-10-21 2020-05-21 Takeda Pharmaceutical Company Limited Assays for determining plasma kallikrein system biomarkers
EA038532B1 (ru) * 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)

Also Published As

Publication number Publication date
JP2022037131A (ja) 2022-03-08
US20180298110A1 (en) 2018-10-18
KR102799778B1 (ko) 2025-04-28
HK1250995A1 (zh) 2019-01-18
WO2016160926A1 (en) 2016-10-06
JP7008920B2 (ja) 2022-01-25
MX2023010206A (es) 2023-09-11
AU2025271115A1 (en) 2025-12-18
BR112017020864A2 (en) 2018-07-10
IL254292B1 (en) 2025-09-01
NZ774543A (en) 2024-04-26
JP7309836B2 (ja) 2023-07-18
AU2022203180A1 (en) 2022-06-02
CN107614532A (zh) 2018-01-19
KR102607829B1 (ko) 2023-12-01
IL305207A (en) 2023-10-01
AU2016243160B2 (en) 2022-02-24
IL254292A0 (en) 2017-10-31
US20220169749A1 (en) 2022-06-02
EP3916020A1 (en) 2021-12-01
KR20250057946A (ko) 2025-04-29
MX2017012423A (es) 2018-01-26
EP3286226A4 (en) 2018-12-05
EA201792161A1 (ru) 2018-04-30
KR20170135885A (ko) 2017-12-08
AU2022203180B2 (en) 2025-09-11
CO2017009404A2 (es) 2018-03-09
JP2023130442A (ja) 2023-09-20
NZ735659A (en) 2023-08-25
KR20230164767A (ko) 2023-12-04
JP2018514510A (ja) 2018-06-07
AU2016243160A1 (en) 2017-10-05
EP3286226A1 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
US12384854B2 (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
US20220169749A1 (en) Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
US20230104754A1 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
HK40064044A (en) Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
HK40057855A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
NZ735659B2 (en) Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
EA046649B1 (ru) Ингибиторы калликреинов плазмы и их применение для профилактики приступа наследственного ангионевротического отека

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180209

EEER Examination request

Effective date: 20180209

EEER Examination request

Effective date: 20180209

EEER Examination request

Effective date: 20180209

EEER Examination request

Effective date: 20180209

EEER Examination request

Effective date: 20180209

EEER Examination request

Effective date: 20180209